Sanctuary Advisors LLC Has $19.22 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sanctuary Advisors LLC increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 2.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,831 shares of the pharmaceutical company's stock after acquiring an additional 928 shares during the quarter. Sanctuary Advisors LLC's holdings in Vertex Pharmaceuticals were worth $19,216,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of VRTX. AlphaCentric Advisors LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter worth about $1,249,000. Americana Partners LLC grew its position in Vertex Pharmaceuticals by 8.0% in the 4th quarter. Americana Partners LLC now owns 12,145 shares of the pharmaceutical company's stock worth $4,891,000 after purchasing an additional 897 shares during the last quarter. Baillie Gifford & Co. grew its position in Vertex Pharmaceuticals by 6.6% in the 4th quarter. Baillie Gifford & Co. now owns 149,838 shares of the pharmaceutical company's stock worth $60,340,000 after purchasing an additional 9,258 shares during the last quarter. Strategic Advisors LLC grew its position in Vertex Pharmaceuticals by 0.6% in the 4th quarter. Strategic Advisors LLC now owns 4,486 shares of the pharmaceutical company's stock worth $1,807,000 after purchasing an additional 25 shares during the last quarter. Finally, Sierra Ocean LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter worth about $60,000. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Up 0.8 %

VRTX stock traded up $3.91 during midday trading on Friday, reaching $484.24. The company had a trading volume of 1,444,007 shares, compared to its average volume of 1,541,286. The company has a market capitalization of $124.35 billion, a P/E ratio of -220.11, a PEG ratio of 2.07 and a beta of 0.41. The company has a 50 day moving average of $436.05 and a two-hundred day moving average of $460.70. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on VRTX shares. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and upped their target price for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. StockNews.com cut shares of Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Wednesday. Wells Fargo & Company cut shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective for the company. in a report on Thursday, January 30th. Finally, HC Wainwright reiterated a "buy" rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $505.61.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the firm's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at $29,438,776.43. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.